Short answer
Cullinan Therapeutics, Inc. (CGEM) filed an 8-K current report with the SEC on August 13, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). Phase 3 REZILIENT3 trial met its primary PFS endpoint at planned interim analysis.
Cullinan Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- Phase 3 REZILIENT3 trial met its primary PFS endpoint at planned interim analysis
- Zipalertinib plus platinum chemotherapy outperformed chemotherapy alone in first-line EGFR exon20ins NSCLC
- Positive data support zipalertinib’s potential label expansion and regulatory submissions
- Taiho collaboration increases commercialization resources and potential milestone economics for Cullinan
Item 8.01 · Other Events
- REZILIENT3 met its primary PFS endpoint, supporting zipalertinib’s efficacy in first-line EGFR exon 20 insertion NSCLC
- Statistically significant and clinically meaningful PFS improvement in the zipalertinib-containing arm
- Manageable observed safety profile, with the Independent Data Monitoring Committee recommending trial unblinding
- Taiho and Cullinan plan U.S. approval pursuit for zipalertinib plus platinum chemotherapy, pending FDA discussions
- Full trial results slated for presentation at an upcoming international medical conference
Item EX-99.1 · Exhibit EX-99.1
- Phase 3 REZILIENT3 met its primary progression-free survival endpoint at planned interim analysis in first-line EGFR exon 20 insertion NSCLC
- Zipalertinib plus platinum chemotherapy delivered statistically significant, clinically meaningful PFS improvement versus chemotherapy alone
- Trial enrolled 285 patients; observed safety for the combination arm was described as manageable
- Independent monitoring committee recommended unblinding; continued efficacy and safety follow-up remains
- Positive data support planned U.S. regulatory discussions and potential approval pursuit, though zipalertinib remains investigational
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Cullinan Therapeutics, Inc. 8-K filings
Get the next CGEM 8-K as it lands
Follow CGEM for push alerts, or ask the research agent what this filing means.